HRP20170042T1 - Farmaceutski pripravak - Google Patents
Farmaceutski pripravak Download PDFInfo
- Publication number
- HRP20170042T1 HRP20170042T1 HRP20170042TT HRP20170042T HRP20170042T1 HR P20170042 T1 HRP20170042 T1 HR P20170042T1 HR P20170042T T HRP20170042T T HR P20170042TT HR P20170042 T HRP20170042 T HR P20170042T HR P20170042 T1 HRP20170042 T1 HR P20170042T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- hydrogen
- cancer
- pharmaceutically acceptable
- image
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 46
- 239000001257 hydrogen Substances 0.000 claims 34
- 229910052739 hydrogen Inorganic materials 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 28
- 150000002431 hydrogen Chemical class 0.000 claims 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 20
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 15
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 5
- 239000001301 oxygen Substances 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 210000001635 urinary tract Anatomy 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- -1 methoxy, difluoromethoxy Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (20)
1. Spoj s formulom I:
[image]
naznačen time da:
jedan od R1a i R1b je vodik, a drugi je metil; ili R1a i R1b se uzimaju zajedno tako da tvore ciklopropilni prsten;
R2 je metil ili fluorometil;
R3 je metil;
R4 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R5 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R6 je vodik, halo, metil, ili metoksi;
R7 je vodik, halo, metil, ili metoksi; i
X je kisik;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1, naznačen time da
jedan od R1a i R1b je vodik, a drugi je metil; R2 je metil, difluorometil, ili trifluorometil;
R3 je metil;
R4 je klor, fluor, trifluorometil, difluorometil, metil, metoksi, difluorometoksi, ili trifluorometoksi;
R5 je vodik, klor, fluor, metil, ili metoksi;
R6 i R7 su vodik;
ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema zahtjevu 2, naznačen time da R5 je vodik; ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema zahtjevu 3, naznačen time da R4 je odabran od klora, trifluorometila, difluorometila, difluorometoksi, i trifluorometoksi; ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema bilo kojem od zahtjeva 1 - 4, naznačen time da, jedan od R1a i R1b je vodik, a drugi je metil, i spoj s formulom I se sastoji od smjese stereoizomera; ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema bilo kojem od zahtjeva 1 - 4, naznačen time da, jedan od R1a i R1b je vodik, a drugi je metil, i spoj s formulom I se sastoji od uglavnom čistog stereoizomera; ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema zahtjevu 6, naznačen time da, jedan od R1a i R1b je vodik, a drugi je metil, i ugljik iz spoja s formulom I označen sa * ima uglavnom S-konfiguraciju; ili njegova farmaceutski prihvatljiva sol.;
8. Spoj prema zahtjevu 6, naznačen time da, jedan od R1a i R1b je vodik, a drugi je metil, i ugljik iz spoja s formulom I označen sa * ima uglavnom R-konfiguraciju; ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema zahtjevu 1, naznačen time da
R1a i R1b se uzimaju zajedno tako da tvore ciklopropilni prsten;
R2 je metil, trifluorometil, ili difluorometil;
R3 je metil;
R4 je trifluorometil, difluorometil, kloro, ili fluoro;
R6 i R7 su vodik;
ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koju čine:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i njegove farmaceutski prihvatljive soli.
11. Spoj prema zahtjevu 10, naznačen time da je:
[image]
ili njegova farmaceutski prihvatljiva sol.
12. Spoj prema zahtjevu 10, naznačen time da je:
[image]
ili njegova farmaceutski prihvatljiva sol.
13. Farmaceutski pripravak naznačen time da sadrži:
(a) spoj s formulom I:
[image]
pri čemu:
jedan od R1a i R1b je vodik, a drugi je metil; ili R1a i R1b se uzimaju zajedno tako da tvore ciklopropil prsten;
R2 je metil ili fluorometil;
R3 je metil;
R4 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R5 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R6 je vodik, halo, metil, ili metoksi;
R7 je vodik, halo, metil, ili metoksi; i
X je kisik;
ili njegovu farmaceutski prihvatljivu sol;
i farmaceutski prihvatljiv nosač, ili
(b) spoj prema zahtjevu 10, ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač, ili
(c) spoj koji je:
[image]
ili njegova farmaceutski prihvatljiva sol;
i farmaceutski prihvatljiv nosač.
14. Farmaceutski pripravak naznačen time da sadrži spoj prema zahtjevu 10 koji je:
[image]
ili njegova farmaceutski prihvatljiva sol;
i farmaceutski prihvatljiv nosač.
15. Farmaceutski pripravak koji sadrži:
(a) spoj s formulom I:
[image]
pri čemu:
jedan od R1a i R1b je vodik, a drugi je metil; ili R1a i R1b se uzimaju zajedno tako da tvore ciklopropilni prsten;
R2 je metil ili fluorometil;
R3 je metil;
R4 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R5 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R6 je vodik, halo, metil, ili metoksi;
R7 je vodik, halo, metil, ili metoksi; i
X je kisik;
ili njegovu farmaceutski prihvatljivu sol, ili
(b) spoj prema zahtjevu 10;
ili njegovu farmaceutski prihvatljivu sol, ili
(c) spoj prema zahtjevu 10 koji je:
[image]
ili njegovu farmaceutski prihvatljivu sol, ili
(d) spoj prema zahtjevu 10 koji je:
[image]
ili njegovu farmaceutski prihvatljivu sol,
naznačen time da je za uporabu za liječenje multiple skleroze kod sisavca.
16. Farmaceutski pripravak koji sadrži:
(a) spoj s formulom I:
[image]
pri čemu:
jedan od R1a i R1b je vodik, a drugi je metil; ili R1a i R1b se uzimaju zajedno tako da tvore ciklopropilni prsten;
R2 je metil ili fluorometil;
R3 je metil;
R4 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R5 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R6 je vodik, halo, metil, ili metoksi;
R7 je vodik, halo, metil, ili metoksi; i
X je kisik;
ili njegove farmaceutski prihvatljive soli, ili
(b) spoj prema zahtjevu 10;
ili njegovu farmaceutski prihvatljivu sol, ili
(c) spoj prema zahtjevu 10 koji je:
[image]
ili njegovu farmaceutski prihvatljivu sol, ili
(d) spoj prema zahtjevu 10 koji je:
[image]
ili njegovu farmaceutski prihvatljivu sol,
naznačen time da je za uporabu za liječenje reumatoidnog artritisa kod sisavca.
17. Farmaceutski pripravak koji sadrži:
(a) spoj s formulom I:
[image]
pri čemu:
jedan od R1a i R1b je vodik, a drugi je metil; ili R1a i R1b se uzimaju zajedno tako da tvore ciklopropilni prsten;
R2 je metil ili fluorometil;
R3 je metil;
R4 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R5 je vodik, halo, fluorometil, metil, metoksi, ili fluorometoksi;
R6 je vodik, halo, metil, ili metoksi;
R7 je vodik, halo, metil, ili metoksi; i
X je kisik;
ili njegove farmaceutski prihvatljive soli, ili
(b) spoj prema zahtjevu 10;
ili njegovu farmaceutski prihvatljivu sol,
naznačen time da je za uporabu za liječenje raka kod sisavca,
pri čemu je rak proizvoljno odabran iz skupine koju čine rak kože, rak dojke, rak debelog crijeva, rak prostate, rak bubrega, rak jajnika, rak grlića maternice, rak endometrija, glioblastom, karcinom pluća, rak glave i vrata, meduloblastom, te rak urinarnog trakta.
18. Farmaceutski pripravak koji sadrži spoj prema zahtjevu 10 koji je:
[image]
ili njegova farmaceutski prihvatljiva sol,
naznačen time da je za uporabu za liječenje raka kod sisavca.
19. Farmaceutski pripravak prema zahtjevu 18, naznačen time da je rak odabran iz skupine koju čine rak kože, rak dojke, rak debelog crijeva, rak prostate, rak bubrega, rak jajnika, rak grlića maternice, rak endometrija, glioblastom, karcinom pluća, rak glave i vrata, meduloblastom, te rak urinarnog trakta.
20. Farmaceutski pripravak koji sadrži spoj prema zahtjevu 10 koji je:
[image]
ili njegova farmaceutski prihvatljiva sol,
naznačen time da je za uporabu za liječenje raka kod sisavca,
pri čemu je rak proizvoljno odabran iz skupine koju čine rak kože, rak dojke, rak debelog crijeva, rak prostate, rak bubrega, rak jajnika, rak grlića maternice, rak endometrija, glioblastom, karcinom pluća, rak glave i vrata, meduloblastom, te rak urinarnog trakta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478110P | 2010-09-21 | 2010-09-21 | |
| EP11760631.9A EP2619182B1 (en) | 2010-09-21 | 2011-09-12 | Pharmaceutical composition |
| PCT/US2011/051163 WO2012039972A1 (en) | 2010-09-21 | 2011-09-12 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170042T1 true HRP20170042T1 (hr) | 2017-03-10 |
Family
ID=44674894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170042TT HRP20170042T1 (hr) | 2010-09-21 | 2017-01-11 | Farmaceutski pripravak |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8686018B2 (hr) |
| EP (2) | EP2619182B1 (hr) |
| JP (1) | JP5956448B2 (hr) |
| KR (1) | KR101911105B1 (hr) |
| CN (1) | CN103097358B (hr) |
| AU (1) | AU2011305872B2 (hr) |
| BR (1) | BR112013002484B1 (hr) |
| CA (1) | CA2806121C (hr) |
| CL (1) | CL2013000675A1 (hr) |
| CY (1) | CY1118680T1 (hr) |
| DK (1) | DK2619182T3 (hr) |
| ES (1) | ES2610185T3 (hr) |
| HR (1) | HRP20170042T1 (hr) |
| HU (1) | HUE031408T2 (hr) |
| IL (1) | IL224288A (hr) |
| LT (1) | LT2619182T (hr) |
| ME (1) | ME02575B (hr) |
| MX (1) | MX2013003162A (hr) |
| MY (1) | MY162146A (hr) |
| NZ (1) | NZ606629A (hr) |
| PE (1) | PE20131343A1 (hr) |
| PL (1) | PL2619182T3 (hr) |
| PT (1) | PT2619182T (hr) |
| RS (1) | RS55566B1 (hr) |
| RU (1) | RU2606510C2 (hr) |
| SG (1) | SG188188A1 (hr) |
| SI (1) | SI2619182T1 (hr) |
| SM (1) | SMT201700008B (hr) |
| UA (1) | UA113499C2 (hr) |
| WO (1) | WO2012039972A1 (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| SI3009426T1 (en) * | 2013-06-12 | 2018-06-29 | Kaken Pharmaceutical Co., Ltd. | 4-alkynyl imidazole derivatives and a drug containing it as an active ingredient |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| AU2015264102C1 (en) * | 2014-05-23 | 2020-10-08 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of cancer |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| WO2017014323A1 (en) | 2015-07-23 | 2017-01-26 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
| KR102684436B1 (ko) | 2015-10-16 | 2024-07-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Ep4 길항제 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AR111874A1 (es) | 2017-05-18 | 2019-08-28 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| SI3625224T1 (sl) | 2017-05-18 | 2021-11-30 | Idorsia Pharmaceuticals Ltd | N-substituirani indolni derivati |
| PE20191814A1 (es) | 2017-05-18 | 2019-12-27 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| LT3625228T (lt) | 2017-05-18 | 2021-10-25 | Idorsia Pharmaceuticals Ltd | Pirimidino dariniai, kaip pge2 receptoriaus moduliatoriai |
| WO2018210987A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| AU2019214193B2 (en) * | 2018-02-05 | 2022-06-16 | Foshan Ionova Biotherapeutics Co., Inc. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
| KR20220143062A (ko) * | 2020-03-04 | 2022-10-24 | 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 | 신규 ep4 길항제의 합성 및 암과 염증에서의 이의 용도 |
| CN114075140A (zh) * | 2020-08-18 | 2022-02-22 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | Ono Pharmaceutical Co | CANCER TREATMENT BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
| TW202227089A (zh) | 2020-11-30 | 2022-07-16 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| TW202246217A (zh) * | 2021-01-28 | 2022-12-01 | 大陸商深圳晶泰科技有限公司 | 咪唑醯胺衍生物及其製備方法和應用 |
| CA3230557A1 (en) * | 2021-09-03 | 2023-03-09 | Xuejun Zhang | Ep4 antagonist compound as well as salt, polymorph, and use thereof |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| CA3242277A1 (en) | 2021-12-23 | 2023-06-29 | Eisai R&D Management Co., Ltd. | Crystalline salt form of ep4 antagonist |
| WO2023125724A1 (zh) * | 2021-12-30 | 2023-07-06 | 杭州阿诺生物医药科技有限公司 | 一种固体药物组合物 |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0421671A (ja) * | 1990-05-16 | 1992-01-24 | Mitsubishi Kasei Corp | ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| TW591020B (en) | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| FR2847160A1 (fr) | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| AU2004259662B2 (en) * | 2003-06-26 | 2008-08-07 | Mereo Biopharma 1 Limited | 5-membered heterocycle-based p38 kinase inhibitors |
| WO2005021508A1 (en) | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| GT200500013A (es) | 2004-01-23 | 2005-08-10 | Amidas herbicidas | |
| AP2006003769A0 (en) * | 2004-05-04 | 2006-10-31 | Pfizer | Ortho substituted aryl or heteroaryl amide compounds |
| CA2565813C (en) * | 2004-05-04 | 2010-10-26 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US20090131470A1 (en) * | 2005-06-11 | 2009-05-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| JP4276280B2 (ja) | 2005-11-21 | 2009-06-10 | 塩野義製薬株式会社 | Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
| EP1988081B1 (en) * | 2006-02-06 | 2012-10-17 | Taisho Pharmaceutical Co., Ltd | Binding inhibitor of sphingosine-1-phosphate |
| JP5183628B2 (ja) | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体 |
| JP5259592B2 (ja) | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
| NZ577109A (en) | 2006-12-15 | 2011-12-22 | Glaxo Group Ltd | Benzamide derivatives as ep4 receptor agonists |
| AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| US7560936B1 (en) | 2007-04-24 | 2009-07-14 | Integrated Device Technology, Inc. | Method and apparatus for ground bounce and power supply bounce detection |
| ATE520667T1 (de) | 2007-06-15 | 2011-09-15 | Basf Se | Verfahren zur herstellung difluormethylsubstituierter pyrazolverbindungen |
| EP2172447A4 (en) * | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| MX2009014159A (es) | 2007-07-19 | 2010-03-04 | Lundbeck & Co As H | Amidas heterocíclicas de 5-miembros y compuestos relacionados. |
| AR067744A1 (es) | 2007-07-31 | 2009-10-21 | Bayer Cropscience Sa | Derivados fungicidas de (hetero) aril- metilen -n- cicloalquil carboxamida condensados de 6 elementos con n |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| WO2009137338A1 (en) | 2008-05-06 | 2009-11-12 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| AU2009247262B2 (en) * | 2008-05-14 | 2013-01-31 | Astellas Pharma Inc. | Amide compound |
| PL2310360T3 (pl) | 2008-08-01 | 2013-07-31 | Bayer Ip Gmbh | Grzybobójcze pochodne N-cykloalkilo-N-bifenylometylo-karboksamidu |
| EP2320906B1 (en) * | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| JP2012503605A (ja) | 2008-09-25 | 2012-02-09 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのベータ−カルボリンスルホニルウレア誘導体 |
-
2011
- 2011-09-12 HU HUE11760631A patent/HUE031408T2/en unknown
- 2011-09-12 PT PT117606319T patent/PT2619182T/pt unknown
- 2011-09-12 SI SI201131067A patent/SI2619182T1/sl unknown
- 2011-09-12 LT LTEP11760631.9T patent/LT2619182T/lt unknown
- 2011-09-12 PL PL11760631T patent/PL2619182T3/pl unknown
- 2011-09-12 KR KR1020137004494A patent/KR101911105B1/ko active IP Right Grant
- 2011-09-12 ME MEP-2017-3A patent/ME02575B/me unknown
- 2011-09-12 CA CA2806121A patent/CA2806121C/en active Active
- 2011-09-12 ES ES11760631.9T patent/ES2610185T3/es active Active
- 2011-09-12 WO PCT/US2011/051163 patent/WO2012039972A1/en active Application Filing
- 2011-09-12 BR BR112013002484-4A patent/BR112013002484B1/pt active IP Right Grant
- 2011-09-12 MY MYPI2013700146A patent/MY162146A/en unknown
- 2011-09-12 MX MX2013003162A patent/MX2013003162A/es active IP Right Grant
- 2011-09-12 RU RU2013118209A patent/RU2606510C2/ru active
- 2011-09-12 EP EP11760631.9A patent/EP2619182B1/en active Active
- 2011-09-12 CN CN201180045222.XA patent/CN103097358B/zh active Active
- 2011-09-12 AU AU2011305872A patent/AU2011305872B2/en active Active
- 2011-09-12 EP EP16161460.7A patent/EP3061751A1/en not_active Withdrawn
- 2011-09-12 RS RS20170008A patent/RS55566B1/sr unknown
- 2011-09-12 SG SG2013007174A patent/SG188188A1/en unknown
- 2011-09-12 DK DK11760631.9T patent/DK2619182T3/en active
- 2011-09-12 NZ NZ60662911A patent/NZ606629A/en unknown
- 2011-09-12 JP JP2013530177A patent/JP5956448B2/ja active Active
- 2011-09-12 UA UAA201304961A patent/UA113499C2/uk unknown
- 2011-09-12 PE PE2013000320A patent/PE20131343A1/es active IP Right Grant
-
2013
- 2013-01-17 IL IL224288A patent/IL224288A/en active IP Right Grant
- 2013-03-12 CL CL2013000675A patent/CL2013000675A1/es unknown
- 2013-03-12 US US13/795,768 patent/US8686018B2/en active Active
-
2014
- 2014-02-05 US US14/173,170 patent/US9000024B2/en active Active
-
2017
- 2017-01-09 SM SM201700008T patent/SMT201700008B/it unknown
- 2017-01-11 HR HRP20170042TT patent/HRP20170042T1/hr unknown
- 2017-01-19 CY CY20171100079T patent/CY1118680T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170042T1 (hr) | Farmaceutski pripravak | |
| JP2013538825A5 (hr) | ||
| HRP20161074T1 (hr) | Benzoksazolski inhibitori kinaza i postupci njihove upotrebe | |
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| HRP20211392T1 (hr) | INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA | |
| HRP20221289T1 (hr) | Supstituirani alkoksipiridinil indolsulfonamidi | |
| GEP20237497B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| EA201891544A1 (ru) | Ингибиторы простатического специфического мембранного антигена (псма) на основе мочевины для визуализации и лечения | |
| GEP20156366B (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| FI3882250T3 (fi) | TETRAHYDROPYRANYYLIAMINO-PYRROLOPYRIMIDINONI KÄYTETTÄVÄKSI HOIDETTAESSA BTK-VÄLITTEISiÄ HÄIRIÖITÄ | |
| JP2011126896A5 (hr) | ||
| PH12015500460A1 (en) | Coated pharmaceutical composition containing regorafenib | |
| FR2953142B1 (fr) | Appareil de delivrance regulee d'un gaz,notamment appareil d'assistance respiratoire | |
| NZ617773A (en) | Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved | |
| GB201200718D0 (en) | Improved pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof | |
| MX371008B (es) | Polvos pulmonares de ultra baja densidad. | |
| MX2020005736A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| PH12015500088A1 (en) | Process for improved opioid synthesis | |
| UY33350A (es) | Procedimiento de preparacion de composiciones farmaceuticas destinadas a la administracion por via oral que comprenden uno 0 varios principos activos y las composiciones que las comprenden | |
| JP2015103770A5 (hr) | ||
| TW200720243A (en) | Process for stably operating a continuous preparation process for obtaining acrolein or acrylic acid or a mixture thereof from propane | |
| FR2910081B1 (fr) | Appareil de delivrance regulee d'un gaz,notamment appareil d'assistance respiratoire |